Post-exposure Therapy with Recombinant Human BuChE Following Percutaneous VX Challenge in Guinea-pigs

Overview

Journal Toxicol Lett

Publisher Elsevier

Specialty Toxicology

Date 2011 May 31

PMID 21620937

Citations 11

Authors

Helen Mumford

John K Troyer

Affiliations

Soon will be listed here.

Abstract

Poisoning by nerve agents via the percutaneous (p.c.) route is an issue because the slow absorption of agent could result in poisoning which outlasts the protection provided by conventional pharmacological therapy. The bioscavenger approach is based on the concept of binding nerve agent in the bloodstream, thus preventing nerve agent from reaching the target tissues and inhibiting acetylcholinesterase activity. One bioscavenger that has been extensively studied is human butyrylcholinesterase (huBuChE). Protexia® is a pegylated form of recombinant huBuChE. We used a guinea-pig model of p.c. nerve agent poisoning, using an implanted telemetry system to collect physiological data. Guinea-pigs were poisoned with the nerve agent VX (0.74 mg/kg) (∼2.5 × LD₅₀). Two hours following VX exposure, Protexia (72 mg/kg) or saline control was administered intramuscularly. All guinea-pigs treated with Protexia (n=8) survived, compared to no survivors in a saline-treated control group (n=8). Survival following VX and Protexia treatment was associated with minimal incapacitation and observable signs of poisoning, and the mitigation or prevention of the detrimental physiological changes (e.g. seizure, bradycardia and hypothermia) observed in control animals. The opportunity for post-exposure treatment may have utility in both civilian and military scenarios, and this is a promising indication for the use of a bioscavenger.

Citing Articles

Chemical, Physical, and Toxicological Properties of V-Agents.

Pampalakis G, Kostoudi S Int J Mol Sci. 2023; 24(10).

PMID: 37239944 PMC: 10218410. DOI: 10.3390/ijms24108600.

Three-dimensional brain-on-chip model using human iPSC-derived GABAergic neurons and astrocytes: Butyrylcholinesterase post-treatment for acute malathion exposure.

Liu L, Koo Y, Russell T, Gay E, Li Y, Yun Y PLoS One. 2020; 15(3):e0230335.

PMID: 32163499 PMC: 7067464. DOI: 10.1371/journal.pone.0230335.

Enzymatic detoxification of organophosphorus pesticides and related toxicants.

Alejo-Gonzalez K, Hanson-Viana E, Vazquez-Duhalt R J Pestic Sci. 2018; 43(1):1-9.

PMID: 30363124 PMC: 6140661. DOI: 10.1584/jpestics.D17-078.

Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead.

Iyengar A, Pande A Protein J. 2016; 35(6):424-439.

PMID: 27830420 DOI: 10.1007/s10930-016-9686-6.

Sarin (GB, O-isopropyl methylphosphonofluoridate) neurotoxicity: critical review.

Abou-Donia M, Siracuse B, Gupta N, Sobel Sokol A Crit Rev Toxicol. 2016; 46(10):845-875.

PMID: 27705071 PMC: 5764759. DOI: 10.1080/10408444.2016.1220916.

References

Huang Y, Lundy P, Lazaris A, Huang Y, Baldassarre H, Wang B . Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BMC Biotechnol. 2008; 8:50. PMC: 2415180. DOI: 10.1186/1472-6750-8-50. View

Katos A, Conti M, Moran T, Gordon R, Doctor B, Sciuto A . Abdominal bloating and irritable bowel syndrome like symptoms following microinstillation inhalation exposure to chemical warfare nerve agent VX in guinea pigs. Toxicol Ind Health. 2008; 23(4):231-40. DOI: 10.1177/0748233707081720. View

Huang Y, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M . Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci U S A. 2007; 104(34):13603-8. PMC: 1934339. DOI: 10.1073/pnas.0702756104. View

van der Schans M, Lander B, van der Wiel H, Langenberg J, Benschop H . Toxicokinetics of the nerve agent (+/-)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol Appl Pharmacol. 2003; 191(1):48-62. DOI: 10.1016/s0041-008x(03)00216-3. View

Wetherell J, Hall T, Passingham S . Physostigmine and hyoscine improves protection against the lethal and incapacitating effects of nerve agent poisoning in the guinea-pig. Neurotoxicology. 2002; 23(3):341-9. DOI: 10.1016/s0161-813x(02)00082-7. View

Wetherell J, Price M, Mumford H, Armstrong S, Scott L . Development of next generation medical countermeasures to nerve agent poisoning. Toxicology. 2006; 233(1-3):120-7. DOI: 10.1016/j.tox.2006.07.028. View

Cerasoli D, Griffiths E, Doctor B, Saxena A, Fedorko J, Greig N . In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2006; 157-158:363-5. DOI: 10.1016/j.cbi.2005.10.052. View

Wetherell J . Continuous administration of low dose rates of physostigmine and hyoscine to guinea-pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning. J Pharm Pharmacol. 1994; 46(12):1023-8. DOI: 10.1111/j.2042-7158.1994.tb03260.x. View

Mumford H, Price M, Lenz D, Cerasoli D . Post-exposure therapy with human butyrylcholinesterase following percutaneous VX challenge in guinea pigs. Clin Toxicol (Phila). 2011; 49(4):287-97. DOI: 10.3109/15563650.2011.568944. View

10.

Taysse L, Daulon S, Delamanche S, Bellier B, Breton P . Protection against soman-induced neuropathology and respiratory failure: a comparison of the efficacy of diazepam and avizafone in guinea pig. Toxicology. 2006; 225(1):25-35. DOI: 10.1016/j.tox.2006.04.043. View

11.

Castro C, Gresham V, Finger A, Maxwell D, Solana R, Lenz D . Behavioral decrements persist in rhesus monkeys trained on a serial probe recognition task despite protection against soman lethality by butyrylcholinesterase. Neurotoxicol Teratol. 1994; 16(2):145-8. DOI: 10.1016/0892-0362(94)90111-2. View

12.

Joosen M, van der Schans M, van Helden H . Percutaneous exposure to VX: clinical signs, effects on brain acetylcholine levels and EEG. Neurochem Res. 2007; 33(2):308-17. DOI: 10.1007/s11064-007-9508-5. View

13.

Dorandeu F, Foquin A, Briot R, Delacour C, Denis J, Alonso A . An unexpected plasma cholinesterase activity rebound after challenge with a high dose of the nerve agent VX. Toxicology. 2008; 248(2-3):151-7. DOI: 10.1016/j.tox.2008.03.013. View

14.

Mumford H, Price M, Wetherell J . A novel approach to assessing percutaneous VX poisoning in the conscious guinea-pig. J Appl Toxicol. 2007; 28(5):694-702. DOI: 10.1002/jat.1324. View

15.

Saxena A, Sun W, Dabisch P, Hulet S, Hastings N, Jakubowski E . Efficacy of human serum butyrylcholinesterase against sarin vapor. Chem Biol Interact. 2008; 175(1-3):267-72. DOI: 10.1016/j.cbi.2008.05.022. View

16.

Lenz D, Clarkson E, Schulz S, Cerasoli D . Butyrylcholinesterase as a therapeutic drug for protection against percutaneous VX. Chem Biol Interact. 2010; 187(1-3):249-52. DOI: 10.1016/j.cbi.2010.05.014. View

17.

Lenz D, Maxwell D, Koplovitz I, Clark C, Capacio B, Cerasoli D . Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact. 2005; 157-158:205-10. DOI: 10.1016/j.cbi.2005.10.025. View

18.

Mumford H, Price M, Cerasoli D, Teschner W, Ehrlich H, Schwarz H . Efficacy and physiological effects of human butyrylcholinesterase as a post-exposure therapy against percutaneous poisoning by VX in the guinea-pig. Chem Biol Interact. 2010; 187(1-3):304-8. DOI: 10.1016/j.cbi.2010.02.020. View

19.

Broomfield C, Maxwell D, Solana R, Castro C, Finger A, Lenz D . Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J Pharmacol Exp Ther. 1991; 259(2):633-8. View

20.

Allon N, Raveh L, Gilat E, Cohen E, Grunwald J, Ashani Y . Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol Sci. 1998; 43(2):121-8. DOI: 10.1006/toxs.1998.2463. View